



STATE BOARD OF OPTOMETRY
2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov



Continuing Education Course Approval Checklist

Title:

Provider Name:

- Completed Application
 - Open to all Optometrists? Yes No
 - Maintain Record Agreement? Yes No
- Correct Application Fee
- Detailed Course Summary
- Detailed Course Outline
- PowerPoint and/or other Presentation Materials
- Advertising (optional)
- CV for EACH Course Instructor
- License Verification for Each Course Instructor
 - Disciplinary History? Yes No

Cashiering and Board Use Only			
Receipt #	Payor ID	Beneficiary ID	Amount
1-3322	5394304	5394304	\$750

BUSINESS, CONSUMER SERVICES, AND HOUSING AGENCY

GOVERNOR EDMUND G. BROWN JR.



STATE BOARD OF OPTOMETRY
2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
P (916) 575-7170 F (916) 575-7292 www.optometry.ca.gov



CONTINUING EDUCATION COURSE APPROVAL APPLICATION

\$50 Mandatory

Pursuant to California Code of Regulations (CCR) § 1536, the Board will approve continuing education (CE) courses after receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR § 1536(g).

In addition to the information requested below, please attach a copy of the course schedule and topical outline of the subject matter. Applications must be submitted 45 days prior to the course presentation date.

Please type or print clearly.

Course Title <u>Waste of the Islands CE II</u> <u>Five Retinal Diagnoses You don't</u> <u>want to miss.</u>	Course Presentation Date <u>8:00 AM - 4:30 PM</u> <div style="display: flex; justify-content: space-around;"> [0][4]/[3][0]/[2][0][1][7] </div>
--	--

Course Provider Contact Information

Provider Name <u>Coastal Vision Medical Group</u> <u>Gina</u> (First) <u>Valdemar</u> (Last) _____ (Middle)		
Provider Mailing Address Street <u>243 S. Main St. #100</u> City <u>Orange</u> State <u>CA</u> Zip <u>92660</u>		
Provider Email Address <u>gina.valdemar@coastal-vision.com</u>		
Will the proposed course be open to all California licensed optometrists?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	
Do you agree to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as the Board requires, for a period of at least three years from the date of course presentation?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	

Course Instructor Information

Please provide the information below and attach the curriculum vitae for each instructor or lecturer involved in the course. If there are more instructors in the course, please provide the requested information on a separate sheet of paper.

Instructor Name <u>Timothy</u> (First) <u>You</u> (Last) _____ (Middle)		
License Number <u>80625</u>	License Type <u>MD</u>	
Phone Number <u>(714) 746-9679</u>	Email Address <u>gina.valdemar@coastal-vision.com</u>	

I declare under penalty of perjury under the laws of the State of California that all the information submitted on this form and on any accompanying attachments submitted is true and correct.

Signature of Course Provider _____

Date 3-17-17



March 23, 2017

State Board of Optometry
2450 Del Paso Road, Ste. 105
Sacramento, CA 95834

RE: Late submission of CE course approval-Taste of the Islands 8 Hour CE-April 30, 2017:
Five Retinal Diagnoses You Don't Want to Miss; Cataract Surgery in Patients with Corneal Pathology;
Buried Treasure: Connecting the Dots to Treating Binocular Misalignment; Patient-reported
Outcomes with Lasik: Interpreting the PROWL study; What We Know about Topography Guided
Refractive Surgery: Case Studies in Clinical Practice; Do You See What I See?; Crosslinking for Corneal
Ectasia: The Evolution of Sclera Lenses; Blink and You'll Miss It: Dry Eye in the Cosmetic Patient; Is the
Symphony Toric Lens the Answer for Every Eye Condition; Should My Glaucoma Patient with a
Cataract have a MIGS Surgery; Vitreous: Friend or Foe; Is it Cancer? The Optometrist Role in the
Diagnosis and Management of Periocular Skin Cancer; Oral Presentations of Systemic Disease: Case
Presentations; Glaucoma Management: What Should I do Next?

Dear Practice and Education committee,

I am writing this letter in regards to late submission for the multi-course symposium titled "Taste of the Islands CE" scheduled for presentation on 04/30/2017. We are short of the 45 day submission request, and wanted to include a letter for late submission with our CE approval application.

We continue to work diligently to get all required items to the board needed for CE approval in a timely manner. Due to multiple speakers at the upcoming CE, we had difficulty obtaining all the lectures to meet the submission requirement timeline and would appreciate your consideration of our continuing education approval request.

Please feel free to reach out to us with any other questions. We look forward to continued relations with the State Board of Optometry and the practice and education committee.

Sincerely,

Gina Valdemar
Affiliate Relations and Education Director
Coastal Vision Medical Group
ginavaldemar@coastal-vision.com

Schedule of Events:

7:00 am-7:50 am	Registration & Breakfast	
7:50 am-8:00 am	Dan B. Tran, MD	Welcome & Opening Remarks
8:00 am-8:25 am	Timothy You, MD	5 Retinal Diagnoses You Don't Want to Miss
8:25 am-8:50 am	Jennifer Lee Wu, MD	Cataract Surgery in Patients with Corneal Pathology
8:50 am-9:15 am	Gary Lovcik, OD	Buried Treasure: Connecting the Dots to Treating Binocular Misalignment
9:15 am-9:40 am	Elizabeth Hofmeister, MD, MC, USN	Patient-reported Outcomes with LASIK: Interpreting the PROWL Study
9:40 am-10:05 am	Dan B. Tran, MD	What We Know about Topography Guided Refractive Surgery: Case Studies in Clinical Practice
10:05 am-10:30 am	Madhu Agarwal, MD	Do You See What I See?
10:30 am-11:00 am	Break	
11:00 am-11:50 am	Jennifer Lee Wu, MD	Crosslinking for Corneal Ectasia
11:50 am-12:15 pm	Justin Kwan, OD, FAAO	The Evolution of Sclera Lenses
12:15 pm-12:40 pm	Jeffrey Joseph, MD	Blink and You'll Miss It: Dry Eye in the Cosmetic Patient
12:40 pm-1:50 pm	Lunch/Luau	
1:50 pm-2:15 pm	Dan B. Tran, MD	Is the Symphony Toric Lens the Answer for Every Eye Condition?
2:15 pm-2:40 pm	Betsy Nguyen, MD	Should My Glaucoma Patient with a Cataract have a MIGS Surgery?
2:40 pm-3:05 pm	Raj Rathod, MD, MBA	Vitreous: Friend or Foe
3:10 pm-3:35 pm	Jeffrey Joseph, MD	Is it Cancer? The Optometrist's Role in the Diagnosis and Management of Periocular Skin Cancer
3:35pm-3:40 pm	Lisa D. Garbutt, MD	Ocular Presentations of Systemic Disease: Case Presentations
4:00 pm-4:25 pm	Betsy Nguyen, MD	Glaucoma Management: What Should I Do Next?
4:25 pm-4:30 pm	Closing Remarks/Raffle	

*At time of print, pending CA Board of Optometry approval. Topics and speakers are subject to change.

**Taste of the Islands 8 hour CE
(1 of 15 lectures)**

Course Title: Five Retinal Diagnoses You Don't Want To Miss

Course Presentation date: 4/30/17

Speaker: Timothy You, MD

Target Audience: This lecture is intended for optometrist seeking continuing education

Course Description:

This lecture seeks to educate optometrists about five key retinal diagnoses, which are likely to be encountered in the management of patients. The conditions which are important to diagnose include: Age-related macular degeneration, traumatic ocular injuries, retinal tumors, retinal tears, retinal detachment, and endophthalmitis. The course will focus on important clinical symptoms, signs, and history taking which will result in accurate diagnoses and improved care of patients.

CE Credit: .50 CE Units

Five Retinal Diagnoses You Don't Want to Miss

Timothy You, MD
Orange County Retina Group
tyou@ocretina.net
Taste of the Islands Conference
April 30, 2017


Outline of Course

- I. **Age-Related Macular Degeneration**
 - a. **Case Study: 74 year old man who had cataract surgery 4 weeks ago. Va 20/20 at one week. Va is 20/60**
 - b. **Dry vs. Wet AMD**
 - c. **Geographic Atrophy**
 - d. **Wet AMD**




- e.
- f. **Clinical Signs seen on SLE and Biomicroscopy**
- II. **Traumatic Ocular Injuries**
 - a. **Trips for Triage**
 - i. **Have high suspicion for injury based on history**
 - ii. **Do not touch globe (doctor or patient)**
 - iii. **Do not dilate or perform tonometry**
 - iv. **Perform Slit lamp; okay to use fluorescein strip for Seidel testing**
 - v. **Do not remove protruding foreign body**
 - vi. **Cover eye with metal or plastic shield**
 - vii. **Keep NPO – nothing to eat**
 - viii. **Call ophthalmologist or retinal doctor ASAP**
 - b. **Favorable Factors**

- c. Good visual acuity
- d. Size of laceration <10mm
- e. Unfavorable Factors
- f. Posterior Wound
- g. Endophthalmitis
- h. Afferent Pupillary Defect suggests Retinal or Nerve Damage
- i. Type of Material is Important
 - i. Reactive Foreign Bodies -
 - ii. Zinc, Aluminum, Copper (Chalcosis), Iron (Siderosis), Steel
 - iii. Inert Non-Metallic Substances -
 - iv. Sand, stone, glass, porcelain, plastic
 - v. Inert Metals -
 - vi. Gold, Silver, Platinum
 - vii. Vegetative -
 - viii. Organic - cilia, fungi, wood



- j. Retinal Tumors
 - a. Benign vs Malignant
 - b. Clinical Features
 - c. Ultrasonography and other Testing



- d.
- e. Management

IV. Retinal Tears and Retinal Detachment

- a. Case presentation: 65 year old patient had cataract surgery 1yr ago. He describes new onset floaters
- b. Epidemiology:
 - i. General incidence 1:10,000-15,000
 - ii. After Cataract 0.66% to 3.6% (1.5%)
 - iii. Occurs after 1 year; mean risk is 11.6mo-26mo (Powell et al, 1995; Olsen et al, 2012)
 - iv. Small, peripheral pseudophakic holes
 - v. Risk Factors: Myopia >6dptr, Aphakia, Trauma, Vitreous Loss, Family Hx, Syndromes
 - vi. Risk for Fellow Eye is up to 12-15%

V. Endophthalmitis

- a. Case presentation: 58 year old man had uneventful cataract surgery. He looked good w/Va 20/30 on POD #1. Two days later. He had blurred vision & eye pain.




b.

c. **Endophthalmitis Vitrectomy Study 1995**

- i. NEI multicenter clinical trial of 855 pts
- ii. Vitrectomy and role of systemic antibx
- iii. Vitrectomy vs. Tap and injection
- iv. Intravit Vanco 1mg/Ceftaz 100mg/Amik 0.4mg
- v. Symptoms: Blurred vision > Pain
- vi. Cultures positive in 69% of cases
- vii. 68% Gram positive coag-negative; 22% gram+ i.e. strep or staph aureus; GN in 6%



VI. **Conclusion and Summary**



**Practical Tips for Better Patient Care:
Five Retinal Diagnoses You Don't
Want to Miss**

Timothy You, MD
Orange County Retina Group
tyou@ocretina.net

Taste of the Islands Conference
April 30, 2017




Background







Dry Macular Degeneration




Geographic Atrophy



Macular Degeneration




Wet Macular Degeneration



Don't Want to Miss #4



History



Traumatic Globe Injuries


- Incidence 3.5 per 100,000 persons annually in United States
- est. 30 cases in Orange County annually
- 18-40% of penetrating globe injuries
- Work injury – metal striking metal such as hammer or chisel
- Document, Document, Document!

Tips for Triage

- Have high suspicion for injury based on history
- Do not touch globe (doctor or patient)
- Do not dilate or perform tonometry
- Perform Slit lamp; okay to use fluorescein strip for Seidel testing
- Do not remove protruding foreign body
- Cover eye with metal or plastic shield
- Keep NPO – nothing to eat
- Call ophthalmologist or retinal doctor ASAP


Prognosis



- **Favorable Factors**
 - Good visual acuity
 - Size of laceration <10mm
- **Unfavorable Factors**
 - Posterior Wound
 - Endophthalmitis
 - Afferent Pupillary Defect suggests Retinal or Nerve Damage




Type of Material is Important


- **Reactive Foreign Bodies –**
 - Zinc, Aluminum, Copper (Chalcosis), Iron (Siderosis), Steel
- **Inert Non-Metallic Substances –**
 - Sand, stone, glass, porcelain, plastic
- **Inert Metals –**
 - Gold, Silver, Platinum
- **Vegetative –**
 - Organic – cilia, fungi, wood













Fishing Line



Extracted Metallic FB






Don't Want to Miss #3


orange county retina

Retinal Examination B-Scan Ultrasound



This slide features a blue background with a white-bordered inset image of a portable ultrasound machine on the left. To the right is a large, high-contrast B-scan ultrasound image of a retina, showing a curved, layered structure with varying echogenicity.


Retinal Examination B-Scan Ultrasound



This slide is similar to the one above, but includes a white-bordered inset image of the ultrasound machine on the left. The B-scan image on the right shows a different view of the retina. In the upper left corner of the B-scan image, the text "G= 88.9dB" is displayed. At the bottom of the B-scan image, a horizontal scale bar is visible with the unit "mm" at its right end.




Don't Want to Miss #2




orange county retina

Case 5




65 year old attorney had cataract surgery 1yr ago. He describes new onset floaters


Case 5



65 year old attorney had cataract surgery 1yr ago. He describes new onset floaters




Retinal Detachment




Retinal Detachment after Cataract Surgery

- **General incidence 1:10,000-15,000**
- **After Cataract 0.66% to 3.6% (1.5%)**
- **Occurs after 1 year; mean risk is 11.6mo-26mo (Powell et al, 1995; Olsen et al, 2012)**
- **Small, peripheral pseudophakic holes**
- **Risk Factors: Myopia >6dptr, Aphakia, Trauma, Vitreous Loss, Family Hx, Syndromes**
- **Risk for Fellow Eye is up to 12-15%**



Horseshoe Retinal Tear



Horseshoe Retinal Tear





Giant Retinal Tear




**Pneumatic
Retinopexy**
SF6 or C3F8 Gas
Tamponade
Cryo/Laserpexy




Retinal Surgery




Retinal Surgery




Scleral Buckling




Case



Choroidal Detachment




Vitrectomy Surgery



Vitreotomy Surgery

Epiretinal Membrane Peeling



The diagram on the left shows a cross-section of the eye with a surgical instrument peeling the epiretinal membrane from the macula. Labels include 'Macula', 'Epiretinal membrane', and 'Optic nerve'. The photograph on the right shows the actual surgical procedure being performed on a patient's eye.

Vitreotomy for Retinal Detachment




orange county retina

Don't Want to Miss #1




Case

58 year old man had uneventful cataract surgery. He looked good w/Va 20/30 on POD #1. Two days later. He had blurred vision & eye pain.



Case 1



Hypopyon
Gr. Pyo=pus,
supporation




Courtesy of Joseph B. Harlan, MD
© Wilmer Eye Institute

Endophthalmitis



Staphylococcal Bacteria



Gr. staphyle grape clusters
Kokkus= berry


Endophthalmitis Vitrectomy Study (1995)


- NEI multicenter clinical trial of 855 pts**
- **Vitrectomy and role of systemic antibx**
 - **Vitrectomy vs. Tap and injection**
 - **Intravit Vanco 1mg/Ceftaz 100mg/Amik 0.4mg**
 - **Symptoms: Blurred vision > Pain**
 - **Cultures positive in 69% of cases**
 - **68% Gram positive coag-negative; 22% gram+ i.e. strep or staph aureus; GN in 6%**

Endophthalmitis Vitrectomy Study (1995)


Results:

- 1. Systemic Antbx don't work
- 2. **Light Perception = PPV**








Light Perception = PPV




Hand Motion = Tap and Inj


Endophthalmitis


+


=




\$16/480cc



\$170/3cc

Resistant Bacteria

70 year old woman dies from carbapenem-resistant Enterobacteriacease (CRE) Klebsiella pneumoniae

- CRE resistant to all known antibiotics (26 available at hospital)
- No treatment available
- Infected Right Hip Seroma
- Osteomyelitis
-




70 year old woman dies from carbapenem-resistant Enterobacteriacease (CRE) Klebsiella pneumoniae

- CRE resistant to all known antibiotics (26 available at hospital)
- No treatment available
- Infected Right Hip Seroma

Chen, et al (MMWR, Sept 2016)

-




Gastrointestinal Scopes

Tainted scope

Duodenoscopes used in ERCP have been tied to several superbug outbreaks.

Annual number of U.S. ERCP procedures


Figures in thousands



Sources: Millennium Research Group, New England Journal of Medicine


What is a duodenoscope?

It's a specialized endoscope put down a patient's throat to treat gallstones, cancers and other digestive issues.



@latimesgraphics

Resistant Bacteria



Gastrointestinal Scopes



Endoscopic-Retrogradecholangiopancreatography Scope

The Longest Word in the English Language

Methionylglutamylarginyltyrosylglutamylserylleucylphenylalanylalanylglutaminylleucyllysylglutamylarginyllysylglutamylglycylalanylphenylalanylvalylprolylphenylalanylvalylthreonylleucylglycylaspartylprolylglucylisoleucylglutamylglutaminiserylleucyllysylisoleucylaspartylthreonylleucylisoleucylglutamylalanylglycylalanylasparylalanylleucylglutamylleucylglycylisoleucylprolylphenylalanylserylaspartylprolylleucelalanylasparylglucylprolylthreonylisoleucylglutaminylasparaginyalanylthreonylleucylarginylalanylphenylalanylalanylalanylglycylvalylthreonylprolylalanylglutaminylcysteinylphenylalanylglutamylmethionylleucylalanylleucylisoleucylarginylglutaminyllsylhistidylprolylthreonylisoleucylprolylisoleucylglycylleucylleucylmethionyltyrosylalanylalanylserylleucylvalylphenylalanylparaginyllsylglycylisoleucylaspartylglutamylphenylalanyltyrosylalanylglutaminylcysteinylglutamyllysylvalylglycylvalylserylvalylleucylvalalanylasparylvalylprolylvalylglutaminyllserylalanylprolylphenylalanylarginylglutaminyalanylalanylleucylarginylhistidylasparaginylvalylalanylprolylisoleucylphenylalanylisoleucylcysteinylprolylprolylasparylalanylasparylasparylspartyleucylleucylarginylglutaminyllsileucylalanylseryltyrosylglycylarginylglycyltyrosylthreonyltyrosylleucylleucylserylargininalanylglycylvalylthreonylglucylalanylglutamylasparaginylarginylalanylalanylleucylprolylleucylasparaginyllhistidylleucylvalylalanyllysylleucyllysylglutamyltyrosylasparaginyalanylalanylprolylprolylleucylglutaminyllsylphenylalanylglycylisoleucylserylalanylprolylasparylglutaminyllsylalanylalanylisoleucylalasparylalanylglycylalanylalanylglucylalanylisoleucylserylglucylserylalanylisoleucylvalyllysylisoleucylisoleucylglutamylglutaminyllhistidylasparaginyllsileucylglutamylprolylglu-0-tamyllysylmethionylleucylalanylalanyoeucyllysylvalylphenylalanylvalylglutamylprolylmethionyllysylalanylalanylthreonylarginylseryne.

This word consists of 1,909 letters. It is the term for the formula C1289H2051N343O375S8. A Tryptophan synthetase A protein, an enzyme that has 267 amino acids.

Orange County Retina Group

Timothy You, MD
tyou@ocretina.net



CURRICULUM VITAE

TIMOTHY T. YOU, M.D. *Fellow, American Academy of Ophthalmology*

Mailing/Contact Address:
Orange County Retina Medical Group
1200 North Tustin Avenue, Suite 140
Santa Ana, California 92705
714-972-8432

PROFESSIONAL PRACTICE AFFILIATIONS

Orange County Retina Medical Group
Physician/Surgeon/Partner
Since 3/1/2005

1200 North Tustin Avenue	Suite 140	Santa Ana, CA 92705	714-972-8432
1200 North Tustin Avenue	Suite 100	Santa Ana, CA 92705	714-972-8432
24022 Calle de la Plata	Suite 475	Laguna Hills, CA 92653	949-581-3618
320 Superior Avenue	Suite 160	Newport Beach, CA 92663	949-646-3242
333 W. Bastanchury Road	Suite 200	Fullerton, CA 92835	714-451-0801
31451 Rancho Viejo Road	Suite 101	San Juan Capistrano, CA 92675	949-496-0611

7/2002-2/2005 Rhode Island Eye Institute, Providence, Rhode Island
7/1999-6/2002 Pacific Clear Vision Institute, Eugene, Oregon

EDUCATION AND TRAINING

Vitreo-Retinal Fellowship

Massachusetts Eye and Ear Infirmary
Harvard Medical School, Boston, Massachusetts, 1997-1999

- Thomas Heed Ophthalmic Fellow, 1997-98
- American Ophthalmological Society, Herman Knapp Fellow, 1998-99

Research Fellowships

Penn Medical Scholars Anatomic Pathology Fellowship
Department of Pathology & Laboratory Medicine
Hospital of the University of Pennsylvania, 1991-1992

Children's Hospital of Los Angeles
University of Southern California, Doheny Eye Institute
Medical Student Fellowship in Pediatric Ophthalmology, 1989

Residency in Ophthalmology

Massachusetts Eye and Ear Infirmary
Harvard Medical School, Boston, Massachusetts, 1994-1997

Internship in Medicine

VA Medical Center, Sepulveda, California
University of California, Los Angeles, 1993-1994

Medical School

Medical Doctorate
University of Pennsylvania School of Medicine
University of Pennsylvania, Philadelphia, Pennsylvania, 1988-1993

Undergraduate Education

Bachelor of Science in Biology with distinction in major & *cum laude*
Yale College, New Haven, Connecticut, 1984-1988

Lab Assistant, Yale School of Medicine, Department of Microbiology, 1987

PROFESSIONAL POSITIONS

- 2013-Present Clinical Rotation Preceptor, Southern California College of Ophthalmology, Fullerton, California
- 2012-Present Preceptor and Site Coordinator, Western University Health Sciences, Pomona, California
- 2012-Present Chief, Department of Ophthalmology, Children's Hospital of Orange County, Orange, California
- 2009-Present Advisor, Clinical Institute, St. Joseph Hospital, Orange, California
- 2010-2012 Member, Planning Committee, Children's Hospital of Orange County Tower, Orange, California
- 2006-Present Expert Witness, Medical Board of California
- 2005-Present Medical Reviewer, MES Group
- 2003-2005 Assistant Clinical Professor in Ophthalmology, Brown Medical School, Providence, Rhode Island
- 2000-Present Medical Reviewer, Advanced Medical Group
- 1997-1999 Assistant Staff, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts

MEDICAL LICENSES

American Board of Ophthalmology, Diplomate, (Board Certified) in 1999
Exam score 95th percentile

American Board of Ophthalmology, Diplomate, (Recertification) in 2009
Maintenance of Certification

Diplomat National Board of Medical Examiners, since 1994

Medical Board of California, since 1993

HOSPITAL AFFILIATIONS

3/1/2005 – Present	Anaheim Regional Medical Center, Anaheim, California
3/1/2005 – Present	Children’s Hospital at Mission, Mission Viejo, California
3/1/2005 – Present	Children's Hospital of Orange County, Orange, California
3/1/2005 – Present	Hoag Memorial Hospital Presbyterian, Newport Beach, California
3/1/2005 – Present	St. Joseph Hospital, Orange, California
3/1/2005 – Present	Western Medical Center, Anaheim, California
3/1/2005 – Present	Western Medical Center, Santa Ana, California

HONORS AND AWARDS

2003	Brown Medical School Award for Excellence in Teaching
1999	Fellow of the Year for Massachusetts Eye and Ear for Excellence in Teaching
1999	Fellow Award at Paul Chandler Lecture for Resident Teaching
1997	STORZ Ophthalmic Instrument Design Contest for Modified Phaco-Chopper
1994-1991	Bill Raskob Foundation Award
1993	History of Medicine Prize, <i>The Stigma of Atomic Bomb Disease</i>
1992	History of Medicine Prize, <i>A Short History of Egyptian Military Ophthalmia</i>
1989	Whanki Essay Contest, <i>The Perfect Painting</i> , second place
1988	Summer Research Internship, Taejon Research Institute, South Korea
1985	Jostens' Scholarship
1985	Elks Club Western-Division Scholarship
1985	Soroptomist Club Scholarship
1985	Orange County Medical Association Scholarship
1984-1988	Mission Community Hospital Auxiliary Scholarship
1982-1984	American Academy of Sciences Junior Scientist, University of Southern California/University of California at Irvine

PROFESSIONAL SOCIETY MEMBERSHIPS

American Academy of Ophthalmology, Fellow
American Society of Retina Specialists (The Vitreous Society)
Association for Research in Vision and Ophthalmology
California Association of Eye Physicians and Surgeons
California Medical Association
California Scholarship Federation
Orange County Society of Ophthalmology
Orange County Medical Association
Oregon Medical Association
Society of Heed Fellows
Society of Penn Medical Scholars
Western Retina Study Club

CLINICAL RESEARCH

01. Genetech, Inc., Protocol #FVF2598g (Marina), Phase IIIb, 2003-2005
Sub-Investigator. *A multicenter, randomized, double masked, sham injection-controlled study of the safety and efficacy of rhuFab V2 in subjects with neovascular AMD who have minimally classic or occult lesion*
02. Eyetech Pharmaceuticals, Protocol #EOP1004, Phase II/III, 2005-2005
Sub-Investigator. *A randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) in patients with exudative AMD*
03. Alcon Research, Ltd., Protocol C-01-99, Phase III, 2005-2005
Sub-Investigator. *A multicenter, double-masked, randomized, parallel groups study to demonstrate efficacy and safety of anecortave treatment relative to Visudyne for AMD.*
04. OxiGENE, Inc., Protocol MMD-213, Phase III, 2005-2006
Sub-Investigator. *A multi-center, randomized, double-masked, placebo-controlled, parallel group, evaluation of the safety and efficacy of combretastatin A4 phosphate infusion for treating subfoveal CNV in pathologic myopia.*
05. Diabetic Retinopathy Clinical Research Network(DRCR)/National Eye Institute, Protocol B, 2005-2009
Sub-Investigator. *A randomized trial comparing intravitreal corticosteroids and laser photocoagulation for DME.*
06. Alcon Research, Ltd., Protocol C-02-60 (AART), Phase III, 2005-2009
Sub-Investigator. *Anecortave Acetate Risk Reduction Trial (AART): An evaluation of efficacy and safety of posterior juxtasclear administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in study "A" or study "B") at risk for developing sight-threatening CNV due to exudative AMD.*
07. National Eye Institute, SCORE, 2005-2009
Sub-Investigator. *The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE): Two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: one for CRVO and one for BRVO.*

08. Lilly ICOS LLC, Protocol H6D-MC-LVGO, Phase IV, Collaborative Study, 2005-2006
Sub-Investigator. *A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of 5mg tadalafil (IC351, LY450190) and 50mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction.*
09. Alcon Research, Ltd., Protocol C0459 (IDEAA), Phase III, 2005-2007
Sub-Investigator. *A trial using anecortave acetate 15mg administered every 3 months versus anecortave acetate 15 mg every 6 months versus anecortave acetate 30 mg administered every 6 with exudative AMD.*
10. Eyetech Pharmaceuticals, Protocol EOP1012, Phase IV, 2005-2007
Sub-Investigator. *A randomized, active-controlled, double-masked, single dummy, multicenter comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen given every 6 weeks for up to 102 weeks, plus sham PDT, to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal CNV secondary to AMD.*
11. Novartis, Protocol CBPD952E2202 (Veritas), Phase IIIB, 2005-2007
Principal Investigator. *A 24-month randomized, double-masked, sham controlled, multicenter study comparing PDT with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal CNV secondary to AMD.*
12. (OSI) Eyetech, Protocol EOP1023 (LEVEL), Phase IV, 2006-2008
Principal Investigator. *An open label, multicenter trial of maintenance intravitreal injections of Macugen (pegaptanib sodium) given every six weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a different modality resulting in maculopathy improvement.*
13. Novartis, Protocol #CBPD952A2308 (Denali), Phase IIIB, 2006-2010
Principal Investigator. *A 24-month randomized, double-masked, controlled, multicenter study assessing safety and efficacy of verteporfin (Visudyne) photodynamic therapy administered in conjunction with ranibizumab (Lucentis) versus ranibizumab (Lucentis) monotherapy in patients with subfoveal CNV secondary to AMD.*
14. Alimera Sciences, Protocol C-01-05-001 (FAME), Phase III, 2006-2011
Sub-Investigator. *Fluocinolone Acetonide in Diabetic Macular Edema (FAME): A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with DME (Medidur®).*
15. Regeneron, Protocol VGFT-OD-0605 (VIEW 1), Phase III, 2006-2011
Sub-Investigator. *Clinical Evaluation of Anti-angiogenesis in the Retina - Intravitreal Trial 3 (CLEAR-IT 3): A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with neovascular AMD.*
16. Opko, Protocol ACU-301 (COBALT), Phase III, 2007-2009
Sub-Investigator. *Combining Bevasirininib and Lucentis Therapy (COBALT): A randomized, double-masked, parallel-assignment study of intravitreal bevasirininib sodium, administered every 8 to 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with exudative AMD.*

17. Allergan, Protocol 206207-012, Phase III, 2007-2010
Sub-Investigator. *A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700 ug dexamethasone posterior-segment drug delivery system (DEX PS DDS) Applicator System in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse DME.*
18. Vitreoretinal Technologies, Inc., Protocol PVD-301, Phase III, 2007-2010
Sub-Investigator. *A safety and efficacy study of Vitreosolve for ophthalmic intravitreal injection for inducing posterior vitreous detachment in subjects with NPDR.*
19. Merck & Co., Protocol 007-01 , Collaborative Study, 2008-2009
Ophthalmology Investigator. *A safety follow-up study of patients previously exposed to MK-0634 (a beta-3 receptor antagonist developed for the treatment of overactive bladder). Subjects had previously been enrolled in a multicenter, double-blind, randomized, placebo-controlled, parallel group, dose-ranging study of L-000796568 in postmenopausal women with OAB.*
20. Allergan, Protocol 206207-019-00, Phase II , 2008-2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in conjunction with Lucentis® in the treatment of patients CNV secondary to AMD.*
21. Ophthotech Corp., Protocol OPH3000, Phase I, 2008-2010
Sub-Investigator. *An ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetic profile of multiple intravitreal injections of volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or in combination with Lucentis 0.5 mg/eye in subjects with neovascular AMD.*
22. Regeneron, Protocol VGFT-OD-0706 (Da Vinci), Phase III, 2008-2011
Sub-Investigator. *A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-eye in patients with DME.*
23. NEI/Tufts Medical Center, The Family Study of Macular Degeneration, 2009-2010
The goal is to evaluate genetic and non-genetic risk factors for AMD
24. Allergan, Protocol 206207-018-00, Phase II, 2008 - 2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in the treatment of vitrectomized subjects with DME.*
25. Grunenthal, Protocol KF0151Y/10, Phase IIb, Collaborative Study, 2009-2011
Sub-Investigator. *A randomized, multicenter, double-blind, parallel-group trial to assess the analgesic efficacy and safety of a new analgesic compared with placebo in subjects with painful diabetic peripheral neuropathy.*
26. Endo Pharmaceuticals, Protocol EN3324-201, Phase IIb, Collaborative Study, 2010-2011
Sub-Investigator. *A randomized, multicenter, double-blind, two-arm, multicenter, placebo-controlled study to assess the efficacy and safety of EN3324 (Axomadol) in subjects with moderate to severe chronic low back pain.*
27. GlaxoSmithKline, Protocol MD 7110852, Phase IIB, 2009-2012
Principal Investigator. *A dose-ranging study of pazopanib eye drops vs. ranibizumab intravitreal injections for the treatment of neovascular AMD.*

28. Genentech, Protocol FVF4579g (HARBOR), Phase III, 2009-2012
Sub-Investigator. *A double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal neovascular AMD.*
29. Lux Biosciences, Inc., Protocol LX211-11, Phase III, 2011-2013
Sub-Investigator. *A multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of Voclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-uveitis.*
30. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA, 2011-Present
Sub-Investigator. *A multicenter, masked, randomized, comparator-controlled study evaluation Isonep™ (sonepcizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to AMD.*
31. Alimera, Protocol C-01-11-008, Extension Study, 2011-2013
Sub-Investigator. *An open-label, multicenter, extension study of the safety and utility of the new inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien® in subjects with DME.*
32. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III, 2012-2013
Sub-Investigator. *A prospective, multi-center, randomized, double-masked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*
33. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II, 2012-2013
Sub-Investigator. *An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema*
34. Xoma, Protocol X052130/CL3-78989-005, Phase III, 2012-Present
Principal Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis*
35. Pfizer, Protocol B1181003-1050, Phase II, 2012-2013
Sub-Investigator. *A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration*
36. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD™ -C), Phase III, 2012-Present
Principal Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment*
37. Regeneron Protocol VGFTe-AMD-1124 ((RE-VIEW), Phase IV, 2012-Present
Sub-Investigator. *Rigorous evaluation of vision and safety with intravitreal aflibercept injection dosed every 8 weeks over 2 years in neovascular AMD*
38. Merck Protocol MK8931—017 (SCH 900931, P07738), Phase 2/3, Collaborative Study, 2012-Present
Ophthalmology Investigator. *A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease*

39. Ophthotech OPH1003, Phase III, 2013-Present
Sub-Investigator. *A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista™ (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular macular degeneration*

ABSTRACTS

01. Wong CG, **You TT**, Ghosen C, Ton L, You L, Burke J, Wheeler L. *Experimental CNV in Cynomolgous Monkey after Sustained Release of VEGF & bFGF within the Suprachoroidal Space*. Association for Research in Vision and Ophthalmology Meeting; May 2011. Abstract
02. Wong CG, **You TT**, Carvalho RAP. Natural history of progressive experimental CNV in the rabbit after sustained release of both VEGF and bFGF within the supra-choroidal space. Association for Research in Vision and Ophthalmology Meeting, May 2009. Abstract
03. Wong CG, Bruce TC, **You TT**. Experimental CNV after transcleral implantation of VEGF/bFGF-implant within the suprachoroidal space for defining potential long-term synergistic actions of ranibizumab (Lucentis) with small low-cost molecules in ameliorating wet AMD. Association for Research in Vision and Ophthalmology Meeting, May 2008. Abstract
04. **You TT**, Wong CG, Fedoruk T, Bonakdar M. Comparison of Lucentis and Avastin in the suprachoroidal VEGF/bFGF-implant rabbit CNV model provides a potential standardized pre-clinical approach in the rational development of more effective QSAR-based drugs, sustained release formulations, and drug delivery systems for ameliorating AMD. Association for Research in Vision and Ophthalmology Meeting, 2007. Abstract
05. Gupta G, Donahue JP, Andorsky S, **You TT**. Profile of the retina by optical coherence tomography in the pediatric age group. Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida; May 1, 2005. Abstract
06. Gupta G, and **You T**. Vitreous Hemorrhage in age-related macular degeneration. New England Ophthalmological Society, Boston, Massachusetts; May 2004. Abstract
07. **You TT** and Itturiaga J. "The Range of Abnormalities in *Drosophila* 1(1)ts-726 after High Temperature Shock Treatments." California Academy of Science Meeting, Los Angeles, California; 1984. Abstract
08. **You T** and Itturiaga J. "Variations in Bristle Pattern After High Temperature Treatment in *Drosophila melanogaster*." American Academy of Science Meeting, New York, New York; 1984. Abstract

PAPERS AND PUBLICATIONS

01. **You TT**, Youn DW, Chen S, Alexandrescu B, Casiano ME, Maggiano JM. Intraocular penetration by acupuncture needle. (submitted for publication, *Retina*)
02. Ambati J, Gragoudas ES, Miller JW, **You TT**, Miyamoto K, Delori FC, Adamis AP. Transscleral delivery of bioactive protein to the choroid and retina. *Invest Ophthalmol Vis Sci* 2000 Apr; 41(5):1186-91.
03. Arroyo JG, **You TT**, Bossi KE. Illuminated lens fixator for bimanual pars plana lensectomy. *Ophthalmic Surg Lasers* 2001 Sep-Oct;32(5):438-40.
04. Rumeldt S, **You TT**, Remulla HD, Rubin PAD, Jakobiec FA. Prepartum mixed type cavernous-capillary hemangioma arising in nevus flammeus. *Ophthalmology* 1999;106:1219-22.
05. **You TT** and Power W. Choroidal detachments and uveal effusion syndrome. In: *Principles and Praxis of Ophthalmology* Vol. 2. Albert DM & Jakobiec F (eds). Saunders. Philadelphia. 1999;1338-1351.
06. **You TT** and JG. Arroyo. Surgical approaches to managing the dislocated crystalline lens. *Int Ophthalmol Clinics* 1999;39:1-12.
07. **You TT** and Kaiser PK, Netland PA, Jakobiec FA. Neurothekeoma palpebrae: a rare nerve sheath tumor arising in the eyelid. *Ophthal Plast Reconstr Surg*. 1999;6:448-9.
08. **You TT** and Young LHY. Retinal manifestations of gastrointestinal disorders. *Int Ophthalmol Clinics* 1998;38:197-220.
09. **You TT**, et al. Corneal Abrasion Patching Study Group. A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. *Ophthalmol* 1997; 104: 1353-59.
10. **You, TT** and Pavan-Langston D. Chronic unilateral keratitis in a young man. *Dig J Ophthalmol* 1995 October 25;Vol. 1. Issue 2.
11. **You, TT** and Dohlman CH. Progressive corneal opacification and arthropathy. *Dig J Ophthalmol* 1995 August 12;Vol. 1, Issue 1.
12. **You TT**, Choi JC, Partington MA, Whitaker LA, Shore JW. "Ophthalmic Findings Associated with Unilateral Non-compensational Plagiocephaly." Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida; 1995. Abstract
13. **You, TT** and Pavan-Langston D. Immune reactions in corneal herpetic disease. *Int Ophthalmol Clinics* 1996;36: 31-39.
14. Menzin AW, **You TT**, Deger RB, J.J. Brooks, S.A. King. Sarcoidosis in a uterine leiomyoma. *Int J Gynaecol Obstet* 1995;48: 79-84.
15. Trojanowski JQ, Mantione JR, Lee JH, Seid DP, **You TT**, Inge LJ, Lee VMY. Neurons derived from a human teratocarcinoma cell line establish molecular and structural polarity following transplantation into the rodent brain. *Exp Neurology* 1993;122: 283-94.

POSTERS & PRESENTATIONS

01. *Updates in Retina Care: Macular Degeneration and Implantable Miniature Telescope*
Course Director. Retina Care Symposium, Costa Mesa, California; December 5, 2013.
02. *Healthcare*
Invited speaker. Third Annual Yorba Linda High School Career Day, Yorba Linda, CA; November 13, 2013.
03. *Updates in Macular Degeneration*
Invited speaker (JCAPHO). South Coast Eye Center, Laguna Hills, California; November 8, 2013.
04. *Cataract Surgery: Retinal Perils, Risks and Complications.*
Invited speaker. NVision Centers, Costa Mesa, California; August 22, 2013.
05. *Retinopathy of Prematurity and Eye Care for Infants*
Invited speaker. Anaheim Regional Medical Center, Anaheim, California; February 21, 2013.
06. *Healthcare*
Invited speaker. Second Annual Yorba Linda High School Career Day, California; November 1, 2012.
07. *Iontophoretic Dexamethasone Phosphate Ophthalmic Suspension in Patients with Non-Infectious Anterior Segment Uveitis: Phase III Data.* Anaheim, California; October 3, 2012.
08. *Updates in Age-Related Macular Degeneration*
Invited speaker. Forest Home Conference Center, Forest Falls, California; July 5, 2012.
09. *Update on Retinal Venocclusive Diseases*
Guest speaker (JCAPHO). South Coast Eye Medical Centers, Laguna Hills, California; March 9, 2012.
10. *Healthcare*
Invited speaker. First Annual Yorba Linda High School Career Day, California; November 8, 2011.
11. *Management of Ophthalmic Emergencies*
Invited speaker. Forest Home Conference Center, Forest Falls, California; July 5, 2011.
12. *Retinal Disease Management*
Invited Speaker, Fuentes de Gracia Hospital Grand Rounds. Chimaltenango, Guatemala; March 2011.
13. *Diabetes and the Eye*
Invited Speaker. St. Joseph's Hospital, Orange, California; February 26, 2011.
14. *Overcoming Retina Hurdles to 20/20 Vision for Your Patients*
Invited Speaker. Orange County Optometric Society, Western Medical Center, California; August 8, 2010
15. *Diabetes and the Eye*
Invited Speaker. St. Joseph's Diabetes Day Conference, St. Joseph Medical Center, Orange, California; February 26, 2010.
16. *Retinopathy of Prematurity and Other Ocular Anomalies*
Invited Speaker. Anaheim Regional Medical Center, Anaheim, California; October 27, 2009.
17. Co-Moderator, Day of Ophthalmology. St. Joseph's Hospital, Orange, California; October 3, 2009.

18. *Retinopathy of Prematurity and Neonatal Eye Diseases*
Invited Speaker. Children's Hospital of Orange at Mission Viejo, California; September 28, 2009.
19. *Retinopathy of Prematurity and Neonatal Eye Diseases*
Invited Speaker. Department of Neonatology, Children's Hospital of Orange County, California; July 13, 2009.
20. *Updates in Ophthalmic Care*
Invited Speaker, Fuentes de Gracia Hospital Grand Rounds, Chimaltenango, Guatemala; July 2009.
21. *Updates on New Treatment for Retinal Diseases*
Invited Speaker. TLC Annual Symposium, Anaheim, California; June 7, 2009.
22. *Macular Degeneration*
Invited Speaker, Foundation for Fighting Blindness. Low Vision Symposium, Southern California College of Optometry, Fullerton, California; May 9, 2009.
23. *The Refractive Surgery Retinal Evaluation: Pearls and Pitfalls*
Invited Speaker. TLC, Newport Beach, California; April 22, 2009.
24. *Retinal Disease Update*
Invited Speaker. Fuentes de Gracia Hospital Grand Rounds, Chimaltenango, Guatemala. August 8, 2008.
25. *Emerging Treatment Strategies for Exudative AMD.*
Novartis Speaker Program. Costa Mesa, California; March 12, 2008.
26. *Emerging Treatment Strategies for Exudative AMD.*
Novartis Speaker Program. Newport Beach, California; February 20 2008.
27. *Retinopathy of Prematurity and Other Ocular Anomalies*
Invited Speaker. Children's Hospital of Orange at Mission. Mission Viejo, California; February 20, 2007.
28. *Toxoplasma Uveitis*
Invited Speaker, Continuing Medical Education Lecture. Children's Hospital of Orange County, Orange, California; October 23. 2006
29. *Retinopathy of Prematurity*
Invited Speaker. Anaheim Regional Medical Center, Anaheim, California; March 14, 2006.
30. *Retinopathy of Prematurity and Neonatal Eye Diseases*
Invited Speaker. Hoag Presbyterian Hospital, Newport Beach, California; July 12, 2005.
31. *The Great Debates: Controversies in Retinal Disease 2005*
Invited Speaker, Medical Education Seminar. University of California, Irvine, Beckman Laser Center, Irvine, California; March 26, 2005.
32. *Pediatrics Case Conference*
Invited Speaker. Rhode Island Hospital, Providence, Rhode Island; January 20, 2003.
33. *Advances in Retina*
Rhode Island Eye Institute, Providence, Rhode Island; 2002.

34. *Posterior Segment*
Posterior Segment Rounds, Central Oregon Optometric Association, Redmond, Oregon; 2001.
35. *Medicine 2000*
Oregon Society of Medical Assisting Conference, Eugene, Oregon; 2000.
36. *Retinal Diagnoses*
Pacific Northwest Conference, Bend, Oregon; 2000.
37. *Retinal Surgery throughout the Ages*
Lane County Optometric Society Meeting, Eugene, Oregon; 1999.
38. **You TT** and Arroyo JG. Surgical approaches to dislocated lenses. Annual Fellows' Conference, Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1998.
39. **You TT** and Young LHY. "Retinal Manifestations of Gastrointestinal Disorders." Biennial Residents' Conference. Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1997.
40. **You TT**, R.N. Hogan, C.S. Foster, C.H. Dohlman. "Corneal Injury in Stevens-Johnson Syndrome." Contact Lens Association of Ophthalmologists Meeting, Las Vegas, Nevada; 1997. Poster
41. **You TT**, Hogan RN, Yuhan KR, Foster CS, C.H. Dohlman. "A Clinicohistopathologic Study of Cornea in Erythema Multiforme Major." Academy of Ophthalmology Meeting, Chicago, Illinois; 1996. Poster
42. **You TT**, Hogan RN, Foster CS, Dohlman CH. "Keratopathy in Stevens-Johnson Syndrome: Histopathologic Study of Diseased Cornea." Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida; 1996. Poster
43. **You TT** and Pavan-Langston D. "Sterile Inflammatory Reactions in Herpes Keratitis." Biennial Residents' Day Conference. Massachusetts Eye & Ear Infirmary, Boston, Massachusetts; 1995.
44. Navon S, **You TT**, Chynn EW. "Eye Examination." NPACE Skills Building Seminar, Framingham, Massachusetts; 1995.
45. *Cognitive Decision Making - A Computer Based Model*
Society of General Internal Medicine Meeting, Washington, DC; 1994.
46. **You TT**, Partington MA, Whitaker LA. "Congenital Torticollis and Plagiocephaly: Clinically Frequent Association." 51st American Cleft Palate and Craniofacial Association Conference, Toronto, Canada; 1994.
47. *Bacterial Utilization of Dissolved Organic Matter in a Natural, Oligotrophic Aquatic System*
California Academy of Science Meeting, Los Angeles, California; 1981.